FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal

The FDA is taking significant steps to tighten oversight of the U.S. drug supply chain by targeting hidden foreign factories that evade U.S. regulatory scrutiny. This move aims to ensure the safety and quality of pharmaceuticals by closing loopholes that allow these facilities to operate outside the U.S. regulatory framework. With a focus on strengthening domestic production, this initiative underscores the FDA's commitment to public health and could lead to more robust safety standards and reduced risks associated with imported drugs. The regulatory overhaul is a crucial development in the ongoing efforts to safeguard American consumers from potential drug safety threats.